Preferred Label : PD-L1 Peptide Vaccine;
NCIt synonyms : PD-L1 Peptide;
NCIt definition : A vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and
immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with
the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic
activities. Vaccination with PD-L1 peptide vaccine may activate the immune system
to induce an immune response against PD-L1-expressing cells. This may increase and
restore the proliferation and activation of various immune cells, including cytotoxic
T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. PD-L1 is overexpressed
on many human cancer cell types as well as on antigen presenting cells (APCs) and
immunosuppressive cells in the tumor micro-environment (TME), such as regulatory T-cells
(Tregs). PD-L1 binding to its cognate receptor programmed cell death protein 1 (PD-1;
PDCD1; CD279) on T-cells suppresses the immune system and results in increased immune
evasion and decreased CTL activation. Montanide ISA-51, also known as incomplete Freund's
adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral
oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated
immune responses to antigens.;
NCI Metathesaurus CUI : CL550798;
Origin ID : C148146;
UMLS CUI : C4724848;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
